Holen Sie sich die Stockscreener-App
130.13
0.04%
0.10
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$130.03
Offen:
$130.74
24-Stunden-Volumen:
3.48M
Relative Volume:
0.62
Marktkapitalisierung:
$200.14B
Einnahmen:
$43.84B
Nettoeinkommen (Verlust:
$13.90B
KGV:
16.32
EPS:
7.9725
Netto-Cashflow:
$6.92B
1W Leistung:
+2.43%
1M Leistung:
+1.20%
6M Leistung:
-3.50%
1J Leistung:
+10.84%
1-Tages-Spanne:
$129.29
$132.03
1-Wochen-Bereich:
$126.55
$132.03
52-Wochen-Spanne:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Vergleichen Sie ABT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
130.07 | 226.11B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
359.58 | 137.72B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.77 | 123.49B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
BSX
Boston Scientific Corp
|
100.06 | 150.85B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
GEHC
Ge Healthcare Technologies Inc
|
70.94 | 32.17B | 20.25B | 2.29B | 1.40B | 4.8366 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
AbbVie Stock Falls 4% -- What Investors Need to Know - The Motley Fool
Sentiment analysis tools applied to Abbott LaboratoriesJuly 2025 Selloffs & Precise Swing Trade Alerts - newser.com
Assessing Abbott Laboratories (ABT) Valuation Potential After Recent Share Price Momentum - simplywall.st
Will earnings trigger a reversal in Abbott LaboratoriesWatch List & Weekly Breakout Stock Alerts - newser.com
Will Abbott Laboratories (ABL) stock benefit from infrastructure billQuarterly Portfolio Report & Accurate Buy Signal Alerts - newser.com
Abbott Laboratories Stock: The Battle for the $140 Threshold - AD HOC NEWS
Can Abbott Laboratories stock surprise with earnings upsideBear Alert & AI Powered Buy and Sell Recommendations - newser.com
Why Is Abbott (ABT) Up 1.3% Since Last Earnings Report? - Yahoo Finance
What Does the Market Think About Abbott Laboratories? - Benzinga
Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger - Yahoo Finance
Is Abbott Laboratories stock a buy on dipsMarket Performance Report & Daily Risk Controlled Trade Plans - newser.com
New data backs Abbott Aveir dual-chamber leadless pacemaker system - MassDevice
Is Abbott Laboratories (Common Stock) (ABL0) stock a top dividend aristocrat candidateQuarterly Earnings Report & Free Fast Gain Swing Trade Alerts - newser.com
Here’s Why Abbott Laboratories (ABT) Traded Down in Q3 - Insider Monkey
Abbott Laboratories Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
FDA expands urgent baby formula recall to all products made by one manufacturer - TheStreet
Citi Reaffirms Buy Rating on Abbott (ABT) Following Favorable Court Ruling - Insider Monkey
Abbott competitor's baby formula recalled after infant botulism outbreak - Crain's Chicago Business
Why pension funds invest in Abbott Laboratories (ABL) stockPortfolio Gains Summary & Daily Growth Stock Investment Tips - newser.com
Unnatural Amino Acids Market to Reach US$ 5.03 Billion By 2032 Driven by Advances in Drug Discovery, Biologics and Protein Engineering - GlobeNewswire Inc.
A Look at Abbott Laboratories’s Valuation Following Revenue Growth and Maintained Outlook - Yahoo Finance
How Investors May Respond To Abbott (ABT) Missing Q3 Revenue Targets While Reaffirming Outlook and Buying Back Shares - Yahoo Finance
Why Abbott Laboratories (ABL) stock could be next leaderQuarterly Investment Review & Long-Term Safe Return Strategies - newser.com
Will a bounce in Abbott Laboratories offer an exit2025 Risk Factors & Growth-Oriented Investment Plans - newser.com
Will Recent Share Buybacks Reshape Abbott’s (ABT) Capital Allocation Story? - simplywall.st
Christine Poole's Top Picks: Abbott Labs, CN Rail & Otis Worldwide - BNN Bloomberg
Abbott Laboratories (ABT): Exploring Valuation After Mixed Q3 Earnings and Bullish Analyst Sentiment - simplywall.st
How Abbott Laboratories stock trades during market volatilityJuly 2025 Review & Risk Controlled Stock Alerts - newser.com
Will Abbott Laboratories (ABL) stock maintain strong growthJuly 2025 Setups & Weekly High Return Forecasts - newser.com
U.S. Functional Protein Market to Get an Explosive Growth| - openPR.com
Is a relief rally coming for Abbott Laboratories holdersWeekly Trend Recap & Free Technical Pattern Based Buy Signals - newser.com
Will Abbott Laboratories stock benefit from infrastructure spendingQuarterly Investment Review & Expert Approved Momentum Trade Ideas - fcp.pa.gov.br
Why Abbott Laboratories (Common Stock) (ABL0) stock is a must watch tickerMarket Activity Recap & AI Optimized Trade Strategies - newser.com
Has Abbott Stock’s Valuation Shifted With Expanded FDA Approvals in 2025? - Yahoo Finance
Why Abbott Laboratories (ABL) stock could outperform next yearQuarterly Trade Report & Expert Curated Trade Ideas - fcp.pa.gov.br
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance
Abbott Laboratories $ABT Stock Holdings Boosted by Dillon & Associates Inc. - MarketBeat
Tufton Capital Management Trims Holdings in Abbott Laboratories $ABT - MarketBeat
Huntington National Bank Trims Holdings in Abbott Laboratories $ABT - MarketBeat
Commonwealth Retirement Investments LLC Acquires Shares of 20,274 Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories' (NYSE:ABT) Earnings Are Weaker Than They Seem - simplywall.st
Jacobson & Schmitt Advisors LLC Acquires Shares of 2,827 Abbott Laboratories $ABT - MarketBeat
Asia-Pacific Organic Baby Food Market Size and Share Analysis Report (2025-2033) Featuring Profiles of Key PlayersAbbott Labs, Nestle, Danone, Kewpie, and Hero Group Among Others - Yahoo Finance
Bank of New York Mellon Corp Cuts Position in Abbott Laboratories $ABT - MarketBeat
With 80% ownership, Abbott Laboratories (NYSE:ABT) boasts of strong institutional backing - Yahoo Finance
Freestone Capital Holdings LLC Cuts Holdings in Abbott Laboratories $ABT - MarketBeat
Is Abbott Laboratories showing signs of accumulation2025 Valuation Update & Precise Buy Zone Identification - newser.com
Q3 Earnings Outperformers: Abbott Laboratories (NYSE:ABT) And The Rest Of The Medical Devices & SuppliesDiversified Stocks - Barchart.com
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.12%
5.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):